| KOMISJA NADZORU FINANSOWEGO | ||||||||||||
| Raport bieżący nr | 23 | / | 2020 | |||||||||
| Data sporządzenia: | 2020-10-22 | |||||||||||
| Skrócona nazwa emitenta | ||||||||||||
| MILESTONE MEDICAL | ||||||||||||
| Temat | ||||||||||||
| Featuring advantages of the CompuFlo® Epidural System and CathCheck™ in interview with a key opinion leader | ||||||||||||
| Podstawa prawna | ||||||||||||
| Art. 17 ust. 1 MAR - informacje poufne. | ||||||||||||
| Treść raportu: | ||||||||||||
| The Board of Directors of Milestone Medical Inc. (WAR: MMD, “the Company”, “the Issuer”, “Milestone”) today announced that Milestone Scientific Inc., the licensor of computer-controlled injection and drug delivery technology and the majority shareholder of Milestone Medical Inc. has published a video interview with a key opinion leader, Dr. Ayman A. Alian, MBChB, Associate Professor of Anesthesiology and Division Chief of Obstetric & Gynecological Anesthesiology at the Yale School of Medicine. The interview, which highlights the advantages of the CompuFlo® Epidural System and CathCheck™, is available at: https://www.milestonescientific.com/news-media/presentations Dr. Alian discusses the benefits of the CompuFlo® Epidural System and CathCheck™, including verification of epidural placement during an epidural procedure and confirmation of catheter placement. The other advantages of CompuFlo® Epidural System and CathCheck™ include: improving the block, helping the medical practitioner to make a decision, decreasing complications and the length of stay in the hospital as well as improving patient satisfaction. The Board of Directors of the Company is grateful to Dr. Alian for his leadership in adopting the CompuFlo® Epidural System and CathCheck™ as part of his practice. The Board of Directors of the Company believes the support from Dr. Alian and other anesthesiologists is further validation of its technology and advances towards the goal of CompuFlo® and CathCheck™ becoming the new standard of care. | ||||||||||||
| MESSAGE (ENGLISH VERSION) | |||
| MILESTONE MEDICAL INC | ||||||||||||||||
| (pełna nazwa emitenta) | ||||||||||||||||
| MILESTONE MEDICAL | ||||||||||||||||
| (skrócona nazwa emitenta) | (sektor wg. klasyfikacji GPW w W-wie) | |||||||||||||||
| NJ 07039 | . | |||||||||||||||
| (kod pocztowy) | (miejscowość) | |||||||||||||||
| South Orange Avenue Livingston | 220 | |||||||||||||||
| (ulica) | (numer) | |||||||||||||||
| +11 973 535 2717 | +11 973 535 2829 | |||||||||||||||
| (telefon) | (fax) | |||||||||||||||
| (e-mail) | (www) | |||||||||||||||
| 27-5484393 | ||||||||||||||||
| (NIP) | (REGON) | |||||||||||||||
| PODPISY OSÓB REPREZENTUJĄCYCH SPÓŁKĘ | |||||
| Data | Imię i Nazwisko | Stanowisko/Funkcja | Podpis | ||
| 2020-10-22 | Joseph D'Agostino | Chief Financial Officer | Joseph D'Agostino | ||
